(Trospium chloride + xanomeline) is under clinical development by Karuna Therapeutics and currently in Phase III for Psychosis. According to GlobalData, Phase III drugs for Psychosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Trospium chloride + xanomeline)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Trospium chloride + xanomeline) overview
Xanomeline in combination with trospium chloride is under development for the treatment of psychosis, negative and cognitive symptoms associated with dementia, dementia-related psychosis, schizophrenia as an adjunctive treatment for psychosis associated with Alzheimer’s disease. It is administered orally. The drug candidate act by targeting muscarinic acetyl choline receptors. It was also under development for the treatment of bipolar disorder and pain.
Karuna Therapeutics overview
Karuna Therapeutics, formerly Karuna Pharmaceuticals, is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia, and Alzheimer’s disease. The company is also evaluating muscarinic-targeted and target-agnostic drug candidates for various indications. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of (Trospium chloride + xanomeline)’s drug-specific PTSR and LoA scores, buy the report here.